Researchers identified trimethylamine (TMA) as a gut microbe–derived metabolite that directly inhibits IRAK4 to reduce metabolic inflammation and improve glycaemic control in high-fat-diet-fed mice. Choline-driven increases in TMA production replicated these benefits, revealing a host–microbe signaling axis with therapeutic potential for obesity-associated insulin resistance.